Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)

Jeffrey Crawford, Carla M.M. Prado, Mary Ann Johnston, Richard J. Gralla, Ryan P. Taylor, Michael L. Hancock, James T. Dalton

Research output: Contribution to journalReview articlepeer-review

97 Scopus citations

Fingerprint

Dive into the research topics of 'Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)'. Together they form a unique fingerprint.

Medicine & Life Sciences